2024
Cognitive Behavioral Therapy and Lisdexamfetamine, Alone and Combined, for Binge-Eating Disorder With Obesity: A Randomized Controlled Trial
Grilo C, Ivezaj V, Tek C, Yurkow S, Wiedemann A, Gueorguieva R. Cognitive Behavioral Therapy and Lisdexamfetamine, Alone and Combined, for Binge-Eating Disorder With Obesity: A Randomized Controlled Trial. American Journal Of Psychiatry 2024, 182: 209-218. PMID: 39659158, PMCID: PMC11786997, DOI: 10.1176/appi.ajp.20230982.Peer-Reviewed Original ResearchCognitive-behavioral therapyBinge-eating disorderEffectiveness of cognitive-behavioral therapyBinge-eating remission ratesEating-disorder psychopathologyCognitive behavioral therapyEvidence-based treatmentsRemission ratePercent weight lossHigher remission ratesBinge-eating frequencyBehavioral therapyPosttreatment assessmentLisdexamfetamineRandomized Controlled TrialsHeightened ratesCostly public health problemIntention-to-treat ratesFunctional impairmentWeight lossControlled TrialsDisordersPosttreatmentIndividualized treatmentMixed models
2023
Does Symptom-Onset Treatment With Sertraline Improve Functional Impairment for Individuals With Premenstrual Dysphoric Disorder?
Yonkers K, Altemus M, Gilstad-Hayden K, Kornstein S, Gueorguieva R. Does Symptom-Onset Treatment With Sertraline Improve Functional Impairment for Individuals With Premenstrual Dysphoric Disorder? Journal Of Clinical Psychopharmacology 2023, 43: 320-325. PMID: 37212651, PMCID: PMC10313784, DOI: 10.1097/jcp.0000000000001700.Peer-Reviewed Original ResearchConceptsPremenstrual dysphoric disorderFunctional impairmentSymptom onsetPMDD symptomsDysphoric disorderAnger/irritabilityDaily treatmentActive treatmentFunctional outcomeClinical trialsFunctional improvementSecondary analysisCausal mediation analysisSertralineSeverity of problemsImpairmentNonsignificant direct effectDaily ratingsPlaceboTreatmentFace validitySymptomsIrritabilityDisordersSignificant indirect effect
2022
Naltrexone-Bupropion and Behavior Therapy, Alone and Combined, for Binge-Eating Disorder: Randomized Double-Blind Placebo-Controlled Trial
Grilo CM, Lydecker JA, Fineberg SK, Moreno JO, Ivezaj V, Gueorguieva R. Naltrexone-Bupropion and Behavior Therapy, Alone and Combined, for Binge-Eating Disorder: Randomized Double-Blind Placebo-Controlled Trial. American Journal Of Psychiatry 2022, 179: 927-937. PMID: 36285406, PMCID: PMC9722598, DOI: 10.1176/appi.ajp.20220267.Peer-Reviewed Original ResearchConceptsBehavioral weight loss therapyBinge-eating disorderPlacebo groupBupropion groupWeight lossRandomized double-blind placebo-controlled trialDouble-blind placebo-controlled trialLogistic regressionBinge-eating remissionPlacebo-controlled trialWeight loss therapyDouble-blind placeboSerious public health problemPublic health problemEvidence-based treatmentsRate of participantsBinge-eating frequencyBinge Eating DisorderMedical comorbiditiesRemission rateLoss therapyPercent weight lossMixed modelsFunctional impairmentSecondary measures
2020
Naltrexone + Bupropion Combination for the Treatment of Binge-eating Disorder with Obesity: A Randomized, Controlled Pilot Study
Grilo CM, Lydecker JA, Morgan PT, Gueorguieva R. Naltrexone + Bupropion Combination for the Treatment of Binge-eating Disorder with Obesity: A Randomized, Controlled Pilot Study. Clinical Therapeutics 2020, 43: 112-122.e1. PMID: 33218742, PMCID: PMC7902424, DOI: 10.1016/j.clinthera.2020.10.010.Peer-Reviewed Original ResearchConceptsBinge-eating disorderEating-disorder psychopathologyPilot RCTTreatment of BEDOutcome time pointDouble-blind treatmentPercentage of patientsControlled Pilot StudyDiscontinuation of medicationTreatment of bingeEvidence-based treatmentsBinge-eating frequencyBupropion combinationAdult patientsAdverse eventsComorbid obesitySecondary outcomesPrimary outcomeAcute effectsFunctional impairmentPlaceboLong-term effectsPatientsMost outcomesObesity
2017
A Multisite Benchmarking Trial of Capnometry Guided Respiratory Intervention for Panic Disorder in Naturalistic Treatment Settings
Tolin DF, McGrath PB, Hale LR, Weiner DN, Gueorguieva R. A Multisite Benchmarking Trial of Capnometry Guided Respiratory Intervention for Panic Disorder in Naturalistic Treatment Settings. Applied Psychophysiology And Biofeedback 2017, 42: 51-58. PMID: 28194546, PMCID: PMC5344940, DOI: 10.1007/s10484-017-9354-4.Peer-Reviewed Original ResearchConceptsPanic disorderRespiratory interventionsTreatment settingsTreatment of PDGlobal illness severityTreat response rateNaturalistic treatment settingEnd-tidal CO2Normocapnic rangeRemission rateIllness severityPresent studyClinical resultsFunctional impairmentRepresentative patientsResponse rateClinical settingSimilar outcomesHypocapnic rangeSimilar decreasePanic severityInterventionHome useCliniciansClient adherence
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply